Dow R. Wilson retired as CEO and Director of Varian upon the sale of the company to Siemens Healthineers in the spring of 2021. He remains an Advisor to Siemens Healthineers. Varian was a NYSE listed cancer equipment and services company with annual sales over $3B and a market cap over $16B. He transformed the company from a traditional capital equipment company to a double digit sales and earnings growth company with a dynamic brand and strategy. He refocused the company portfolio by spinning out a radiology components business and doubling down aggressively on the company’s strong reputation in cancer. He oversaw key acquisitions into cancer clinical services, software, interventional oncology, and global expansion. At the same time, nearly doubled investment (as a % of sales) in organic initiatives several of which became billion dollar global product platforms. He joined Varian in 2005 as President of the Oncology business and later became COO before his appointment as CEO in 2012. Prior to Varian, He worked in senior executive roles at General Electric where he ran significant businesses in both Healthcare and Plastics.
He has served on several company boards and is currently Director and Audit Chair at Agilent. He also was on the Board and Chair of the Technology and Regulatory Committee at AdvaMed. He continues to serve on the board of the US-India Strategic Partnership Forum. From 2014 to 2020 Dow served by appointment from the US Secretary of Commerce on the President’s Advisory Council on Doing Business in Africa and later on the CEO Forum for Brazil, where Dow served as co-chair.
A graduate of Brigham Young University, He also holds an MBA from the Amos Tuck School of Business at Dartmouth.